WBC100 capsule for relapsed or refractory AML
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests an experimental capsule called WBC100 for people whose leukemia has come back or hasn't responded to standard treatments. It aims to see if the drug is safe and if it can help control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have acute myeloid leukemia (AML) that has returned or not improved after treatment.
- You need to be in fairly good health, able to care for yourself (ECOG score 0–2).
- Your organs (like kidneys, liver, heart) must work well enough, as shown by recent blood tests and an echo.
- You cannot have certain other cancers or serious heart problems, and you must not be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug called QHRD107 combined with other medicines for people whose acute myeloid leukemia (AML) has come back or not responded to standard treatments. The goal is to see if the new combination is safe and helps control the leukemia.
This Phase 1 study tests BP1002 in adults with acute myeloid leukemia (AML) that is refractory (not responding) or relapsed (coming back). It’s early-stage, aiming to find a safe dose and see if the treatment can help people with limited options.
This Phase 1 study tests BXCL701 in adults whose acute myeloid leukemia (AML) or high-blast myelodysplastic syndrome (MDS-EB-2) has come back or not responded to prior treatment. The goal is to find a safe dose and see how the treatment affects cancer cells.
This trial tests a new treatment, BG1805, for people with acute myeloid leukemia (AML) that has come back or not responded to standard therapy. It targets a specific marker on leukemia cells called CLL-1.
This early-phase (Phase 1) study tests CAP-100 in adults with CLL or SLL that has come back or did not respond to at least two previous treatments. The goal is to see how the drug works and whether it is safe enough to keep studying.
This trial tests an oral investigational drug (GLB-001) for people with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) that has returned or hasn't responded to other treatments. The goal is to see if it's safe and effective for those who have run out of standard options.
Hear when a new AML (Acute Myelogenous Leukemia) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.